Ascelia Pharma AB (publ)
Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment o… Read more
Ascelia Pharma AB (publ) (ACE) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.137x
Based on the latest financial reports, Ascelia Pharma AB (publ) (ACE) has a cash flow conversion efficiency ratio of -0.137x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-15.66 Million) by net assets (Skr114.40 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Ascelia Pharma AB (publ) - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how Ascelia Pharma AB (publ)'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Ascelia Pharma AB (publ) Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Ascelia Pharma AB (publ) ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Duck Yang Ind
KO:024900
|
0.240x |
|
Avadh Sugar & Energy Limited
NSE:AVADHSUGAR
|
0.864x |
|
Community Bancorp of Santa Maria
OTCQX:CYSM
|
N/A |
|
Northeast Group Berhad
KLSE:0325
|
0.044x |
|
Cuulong Fish JSC
VN:ACL
|
N/A |
|
Turker Proje Gayrimenkul Ve Yatirim Gelistirme AS
IS:TURGG
|
-0.003x |
|
Multicampus Corporation
KQ:067280
|
0.038x |
|
Haulotte Group SA
PA:PIG
|
0.029x |
Annual Cash Flow Conversion Efficiency for Ascelia Pharma AB (publ) (2017–2024)
The table below shows the annual cash flow conversion efficiency of Ascelia Pharma AB (publ) from 2017 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | Skr78.94 Million | Skr-62.84 Million | -0.796x | +53.33% |
| 2023-12-31 | Skr74.33 Million | Skr-126.79 Million | -1.706x | -146.30% |
| 2022-12-31 | Skr180.86 Million | Skr-125.26 Million | -0.693x | -82.92% |
| 2021-12-31 | Skr307.83 Million | Skr-116.56 Million | -0.379x | -4.51% |
| 2020-12-31 | Skr236.06 Million | Skr-85.53 Million | -0.362x | -132.65% |
| 2019-12-31 | Skr237.06 Million | Skr-36.92 Million | -0.156x | -41.74% |
| 2018-12-31 | Skr276.07 Million | Skr-30.33 Million | -0.110x | +41.43% |
| 2017-12-31 | Skr111.73 Million | Skr-20.96 Million | -0.188x | -- |